Familial hypercholesterolemia/autosomal dominant hypercholesterolemia: Molecular defects, the LDL-C continuum, and gradients of phenotypic severity
- 1 July 2016
- journal article
- review article
- Published by Elsevier BV in Journal of Clinical Lipidology
- Vol. 10 (4), 970-986
- https://doi.org/10.1016/j.jacl.2016.04.009
Abstract
No abstract availableThis publication has 91 references indexed in Scilit:
- Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering TherapyPLOS ONE, 2012
- Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial HypercholesterolemiaCirculation, 2012
- Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with theAPOEp.Leu167del MutationHuman Mutation, 2012
- Subjects with Molecularly Defined Familial Hypercholesterolemia or Familial Defective apoB-100 Are Not Being Adequately TreatedPLOS ONE, 2011
- Exome Sequencing,ANGPTL3Mutations, and Familial Combined HypolipidemiaThe New England Journal of Medicine, 2010
- A fourth locus for autosomal dominant hypercholesterolemia maps at 16q22.1European Journal of Human Genetics, 2010
- LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectivesInternational Archives of Medicine, 2010
- Regulation of plasma LDL: the apoB paradigmClinical Science, 2009
- PCSK9: a convertase that coordinates LDL catabolismJournal of Lipid Research, 2009
- Treatment of children with homozygous familial hypercholesterolemia: Safety and efficacy of low-density lipoprotein apheresisThe Journal of Pediatrics, 1992